ClinicalTrials.gg
CompletedNCT00062426Updated Nov 6, 2013

Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer

A Phase 3 interventional study of bevacizumab and capecitabine in Colorectal Cancer, sponsored by Prologue Research International. Completed at 52 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-06.

Sponsored by Prologue Research International · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Started
2003
with 4 others
Phase 3
42 of 230
4 open now
Registered
4th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is one of 5 that started in 2003, is one of 42 in phase 3, and was the 4th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different combinations may kill more tumor cells. Monoclonal antibodies, such as bevacizumab (Avastin™), can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known which regimen works better in treating advanced colorectal cancer.

PURPOSE: This randomized phase III trial is to see if oxaliplatin and bevacizumab work better when combined with either fluorouracil and leucovorin or capecitabine in treating patients who have metastatic or recurrent colorectal cancer.

Read the detailed description

OBJECTIVES:

  • Compare the incidence of grade 3 and 4 toxic effects occurring within the first 12 weeks of treatment with 2 different schedules of oxaliplatin, bevacizumab (Avastin™), leucovorin calcium, and fluorouracil or with oxaliplatin, Avastin™, and capecitabine in patients with advanced colorectal cancer.
  • Compare the overall response rate, progression-free survival, and time to treatment failure in patients treated with these regimens.
  • Compare the composite toxicity of these regimens in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 3 treatment arms.

  • Arm I: Patients receive bevacizumab (Avastin™) IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil (5-FU) IV over 46 hours beginning on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive Avastin™ IV over 30-90 minutes and oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium IV over 10 minutes and 5-FU IV over 3 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
  • Arm III: Patients receive Avastin™ IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed at 1 month, every 3 months for at least 2 years, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 375 patients (125 per treatment arm) will be accrued for this study.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • adenocarcinoma of the colon
  • adenocarcinoma of the rectum
  • recurrent colon cancer
  • stage IV colon cancer
  • recurrent rectal cancer
  • stage IV rectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DISEASE CHARACTERISTICS:

  • confirmed adenocarcinoma of the colon or rectum

    • or recurrent disease not amenable to potentially curative treatment
  • At least 1 unidimensionally at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

    • Histological or cytological confirmation is required for a solitary target lesion
  • No

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • 0-1

  • Not specified

Hematopoietic

  • at least 1,500/mm\^3
  • count at least 100,000/mm\^3

Hepatic

  • no greater than 2 times (ULN)
  • and SGOT no greater than 3 times ULN

Renal

  • Creatinine no greater than 1.5 times ULN
  • at least 30 mL/min

Cardiovascular

  • No myocardial infarction within the past 6 months
  • No clinical evidence of congestive heart failure
  • No unstable coronary artery disease

Pulmonary

  • No interstitial pneumonia
  • No extensive symptomatic fibrosis of the lungs

Gastrointestinal

  • Able to tolerate oral medication
  • No lack of physical integrity of the upper gastrointestinal tract
  • No malabsorption syndrome
  • No swallowing difficulties

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective during and for 6 months after study participation
  • No other concurrent serious illness
  • No uncontrolled infection
  • No other concurrent except nonmelanoma skin cancer or carcinoma in situ of the cervix or any other cancer for which the patient has been off all therapy and in remission for at least 5 years
  • No peripheral neuropathy
  • No to any of the study drugs or their ingredients
  • No known dihydropyrimidine dehydrogenase deficiency
  • No other medical or psychiatric disorder that would preclude giving or complying with study

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No concurrent prophylactic hematopoietic growth factor therapy
  • No prior bevacizumab (Avastin™)

Chemotherapy

  • At least 6 months since prior adjuvant fluorouracil, leucovorin calcium, and irinotecan
  • No prior oxaliplatin
  • No prior chemotherapy for metastatic or recurrent disease
  • No other concurrent chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • No concurrent radiotherapy unless for the control of bone pain

Surgery

  • Recovered from prior surgery
  • No prior organ allografts

Other

  • More than 4 weeks since prior drugs
  • No concurrent iced mouth rinses for the prevention of stomatitis
  • No concurrent cold cap alopecia prevention
  • No concurrent pyridoxine
  • No concurrent sorivudine or chemically-related analogues (e.g., brivudine)
  • No concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, or warfarin
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
06

Study locations

52 sites
  • University of Alabama at Birmingham Comprehensive Cancer Center
    Birmingham, Alabama 35294-3300, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85712, United States
  • California Cancer Care, Inc.
    Greenbrae, California 94904-2007, United States
  • Valley Tumor Medical Group
    Lancaster, California 93534, United States
  • Cancer and Blood Institute of the Desert
    Rancho Mirage, California 92270, United States
  • Rocky Mountain Cancer Centers - Midtown
    Denver, Colorado 80218, United States
  • Northwestern Connecticut Oncology-Hematology Associates
    Torrington, Connecticut 06790, United States
  • Lombardi Cancer Center at Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Lynn Regional Cancer Center West
    Boca Raton, Florida 33428, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Oncology Associates
    Jacksonville, Florida 32207, United States
  • Hematology and Oncology Consultants, P.A.
    Orlando, Florida 32804, United States
  • Hematology Oncology Associates of theTreasure Coast - Port St. Lucie
    Port St. Lucie, Florida 34952, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida 33401, United States
  • Peachtree Hematology and Oncology Consultants, P.C.
    Atlanta, Georgia 30309, United States
  • North Idaho Cancer Center
    Coeur d'Alene, Idaho 83814, United States
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University
    Chicago, Illinois 60611, United States
  • Lutheran General Cancer Care Center
    Park Ridge, Illinois 60068-1270, United States
  • West Suburban Center for Cancer Care
    River Forest, Illinois 60305, United States
  • Saint Anthony Medical Center
    Rockford, Illinois 61108, United States
  • CCOP - Northern Indiana CR Consortium
    South Bend, Indiana 46601, United States
  • Cedar Rapids Oncology Associates
    Cedar Rapids, Iowa 52403-1206, United States
  • CCOP - Wichita
    Wichita, Kansas 67214-3882, United States
  • Greater Baltimore Medical Center and Cancer Center
    Baltimore, Maryland 21204, United States
  • Jackson Oncology Associates, PLLC
    Jackson, Mississippi 39202, United States
  • Veterans Affairs Medical Center - Kansas City
    Kansas City, Missouri 64128, United States
  • Deaconess Billings Clinic Cancer Center
    Billings, Montana 59107-5100, United States
  • Cooper Cancer Institute at Cooper University Hospital
    Voorhees, New Jersey 08043, United States
  • Advanced Oncology Associates
    Armonk, New York 10504, United States
  • North Shore Hematology/Oncology Associates, P.C.
    East Setauket, New York 11733, United States
  • Arena Oncology Associates
    Great Neck, New York 11021, United States
  • St. Vincents Comprehensive Cancer Center
    New York, New York 10011, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Duke Comprehensive Cancer Center
    Durham, North Carolina 27710, United States
  • Southeastern Medical Oncology Center
    Goldsboro, North Carolina 27534, United States
  • Physicians East - Quadrangle
    Greenville, North Carolina 27834, United States
  • Raleigh Hematology/Oncology Associates, P.A. - Wake Practice
    Raleigh, North Carolina 27609-7300, United States
  • Hematology Oncology Consultants Inc
    Columbus, Ohio 43235, United States
  • Hematology/Oncology of Salem
    Salem, Oregon 97301, United States
  • Pennsylvania Oncology Hematology Associates
    Philadelphia, Pennsylvania 19106, United States
  • Hillman Cancer Center at University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15232, United States
  • Charleston Hematology-Oncology, P.A.
    Charleston, South Carolina 29403, United States
  • McCleod Cancer and Blood Center
    Johnson City, Tennessee 37604, United States
  • Memphis Cancer Center
    Memphis, Tennessee 38119, United States
  • West Clinic
    Memphis, Tennessee 38120, United States
  • Sarah Cannon Cancer Center at Centennial Medical Center
    Nashville, Tennessee 37203, United States
  • Lone Star Oncology
    Austin, Texas 78759, United States
  • Medical City Dallas Hospital
    Dallas, Texas 75230, United States
  • South Texas Oncology and Hematology
    San Antonio, Texas 78207, United States
  • Center for Cancer Prevention and Care at Scott and White Clinic
    Temple, Texas 76508, United States
  • Medical Consultants
    Milwaukee, Wisconsin 53215-3690, United States
07

References and documents

Publications

  • Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer. 2011 Feb 1;104(3):413-8. doi: 10.1038/sj.bjc.6606074. Epub 2011 Jan 18. PubMed 21245868 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2003
First posted
Jun 6, 2003
Start
May 2003
CompletionActual
Feb 2011
Last update
Nov 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00062426
Lead sponsor
Prologue Research International
First posted
Jun 6, 2003
Start date
May 2003
Completion
Feb 2011
Last update
Nov 6, 2013

Study contacts

Richard A. Gams, MD
study chair · Prologue Research International
Lauri Welles, MD
Sanofi-Synthelabo
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2004. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Capecitabine · Fluorouracil · Oxaliplatin

Start the discussion